After years of decline, the UK High Court has seen a 32% surge in newly filed patent cases in 2025 — a rebound that places it alongside Munich and the UPC as a popular venue for patent litigation. Yet this revival comes against a backdrop of escalating friction, as British judges, German chambers and the UPC increasingly jostle over interim licences, anti-suit injunctions and global FRAND determinations.

Munich, meanwhile, has been busy demonstrating why it remains the venue of choice for pharmaceutical patentees: the Regional Court granted Merz a sweeping set of preliminary injunctions against multiple generics manufacturers over its MS drug Fampyra, effectively clearing the German market of generic fampridine until the SPC expires in July. This was followed by a decision this week from the UPC Court of Appeal on the French part of the same patent. Furthermore, Sekisui's win against Kuraray in a chemicals case at the Federal Patent Court shows that even rare patent disputes between Japanese companies are now being fought on German soil.

And in Paris, two seasoned litigators from August Debouzy and Aramis have launched a new IP boutique, Pairs Law. One of the founders was featured on JUVE Patent’s Ones to Watch in French patent litigation in 2024.

In other exciting news, JUVE Patent is making room for something new on Wednesdays. Next week, we’ll be switching our Wednesday newsletter to Fridays. More details coming next week – stay tuned!